Leukotrienes in cardiovascular diseases

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 2 II, 2000, Pages

  Folco, Giancarlo ^a   Rossoni, Giuseppe ^a   Buccellati, Carola ^a   Berti, Ferruccio ^a   Maclouf, Jacques ^a   Sala, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; HEART FUNCTION; HEART MUSCLE INJURY; HEART PROTECTION; ICOSANOID METABOLISM; INFLAMMATION; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0034014272     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.supplement_1.ltta-22     Document Type: Article

References (36)

1. Letts, L. G. 1987. Leukotrienes: role in cardiovascular physiology. Cardiovasc. Clin. 18:101-113.
2. 2 and LT are eicosanoid mediators of shock and ischemic disorders. Prog. Clin. Biol. Res. 264:101-114.
3. 4 in man. Int. J. Clin. Lab. Res. 27:178-184.
4. Feuerstein, G. 1984. Leukotrienes and the cardiovascular system. Prostaglandins 27:781-802.
5. Marone, G., G. deCrescenzo, M. Adt, U. Patella, E. Arhustini, and A. Genovese. 1995. Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 31:1-18.
6. Carry, M., V. Korley, J. T. Willerson, J. T. Weigelt, A. W. Ford Hutchinson, and P. Tagari. 1992. Increased urinary LT excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation 85:230-236.
7. Scoggan, K. A., P. J. Jakobsson, and A. W. Ford-Hutchinson. 1997. Production of leukotriene C4 in different human tissues is attributable to distinct membrane bound biosynthetic enzymes. J. Biol. Chem. 272: 10182-10187.
8. Sala, A., G. Rossoni, C. Buccellati, F. Berti, G. C. Folco, and J. Maclouf. 1993. Formation of sulphidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. Br. J. Pharmacol. 110:1206-1212.
9. Baumann, G., G. Riess, W. D. Erhardt, S. B. Felix, L. Ludwig, G. Blümel, and H. Blömer. 1981. Impaired β-adrenergic stimulation in the uninvolved ventricle post-acute myocardial imfarction: reversible defect due to excessive circulating catecholamine-induced decline in number and affinity of beta-receptors. Am. Heart. J. 101:569-581.
10. Schierwagen, C., A. C. Bylund Fellenius, and C. Lundberg. 1990. Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J. Pharmacol. Methods 23:179-186.
11. Buccellati, C., G. Rossoni, A. Bonazzi, F. Berti, J. Maclouf, G. Folco, and A. Sala. 1997. Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart. Br. J. Pharmacol. 120:1128-1134.
12. Rossoni, G., A. Sala, F. Berti, T. Testa, C. Buccellati, C. Molta, R. Muller-Peddinghaus, J. Maclouf, and G. C. Folco. 1996. Myocardial protection by the Ieukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 276:335-341.
13. Allen, S. P., M. R. Dashwood, A. H. Chester, S. Tadjkarimi, M. Collins, P. J. Piper, and M. H. Yacoub. 1993. Influence of atherosclerosis on the vascular reactivity of isolated human epicardial coronary arteries to LTC4. Cardioscience 4:47-54.
14. 4 from human polymorphonuclear leukocytes J. Biol. Chem. 271:17944-17948.
15. 4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 217:841-843.
16. Dahlén, S. E., J. Björk, P. Hedqvist, K.-E. Arfors, S. Hammarström, J.-A. Lindgren, and B. Samuelsson. 1981. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 78:3887-3891.
17. Zimmerman, G. A., S. M. Prescott, and T. M. McIntyre. 1992. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol. Today 13:93-100.
18. Huang, P. L., Z. Huang, H. Mashimo, K. D. Bloch, M. A. Moskowitz, J. A. Bevan, and M. C. Fishman. 1995. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242.
19. McCall, T., B. J. R. Whittle, N. K. Boughto Smith, and S. Moncada. 1988. Inhibition of FMLP-induced aggregation of rabbit neutrophils by NO. Br. J. Pharmacol. 95:517P.
20. Herbaczynska-Cedro, K., K. Lembowicz, and B. Pytel. 1991. NG-monomethyl-L-arginine increases platelet deposition on damaged endothelium in vivo: a scanning electron microscopy study. Thromb. Res. 64: 1-9.
21. Kubes, P., M. Suzuki, and D. N. Granger. 1991. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 88:4651-4655.
22. Carry, M., V. Korley, J. T. Willerson, L. Weigelt, A. W. Ford-Hutchinson, and P. Tagari. 1992. Increased urinary leukotriene excretion in patients with cardiac ischemia: in vivo evidence for 5-lipoxygenase activation. Circulation 85:230-236.
23. Hashimoto, H., K. Miyazawa, M. Hagiwara, K. Miyasaka, and M. Nakashima. 1990. Beneficial effects of a new 5-LOX inhibitor on occlusion and occlusion reperfusion-induced myocardial injury. Arzneim. Forsch. 40:126-129.
24. Sasaki, K., A. Ueno, M. Kawamura, M. Katori, S. Shigehiro, and R. Kikawada. 1987. Reduction of myocardial infarct size in rats by a selective 5-LO inhibitor (AA-861). Adv. Prostaglandin Thromboxane Leukotriene Res. 17:381-383.
25. Amsterdam, E. A., H. L. Pan, S. V. Rendig, J. D. Symons, M. P. Fletcher, and J. C. Longhurst. 1993. Limitation of myocardial infarct size in pigs with a dual LOX-COX blocking agent by inhibition of neutrophil activity without reduction of neutrophil migration. J. Am. Coll. Cardiol. 22:1738-1744.
26. Toki, Y., N. Hieda, T. Torii, H. Hashimoto, T. Ito, K. Ogawa, and T. Satake. 1988. The effect of lipoxygenase inhibitor and Cys-LT antagonist on myocardial injury in a canine coronary occlusion-reperfusion model. Prostaglandins 35:555-571.
27. Mullane, K., M. A. Hatala, R. Kraemer, W. Sessa, and W. Westlin. 1987. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J. Cardiovasc. Pharmacol. 10:398-406.
28. Hahn, R. A., B. R. MacDonald, P. J. Simpson, L. Wang, R. D. Towner, P. P. Ho, M. Goodwin, A. P. Breau, T. Suarez, and E. D. Mihelic. 1991. Characterization of LY233569 on 5-LO and reperfusion injury of ischemic myocardium. J. Pharmacol. Exp. Ther. 256:94-102.
29. Hock, C. E., L. D. Beck, and L. A. Papa. 1992. Peptide LT receptor antagonism in myocardial ischemia and reperfusion. Cardiovasc. Res. 26: 1206-1211.
30. 2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of C5a in pigs. Cir. Res. 66: 596-607.
31. 4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn. Cir. J. 53:1115-1121.
32. 4 receptors and myocardial reperfusion injury. J. Pharmacol. Exp. Ther. 260:979-989.
33. 4 receptors does not limit canine myocardial infarct size. J. Pharmacol. Exp. Ther. 253:58-66.
34. Egan, J. W., D. E. Griswold, L. M. Hillegass, J. F. Newton, R. D. Eckardt, M. J. Slivjak, and E. F. Smith. 1989. Selective antagonism of peptido-LT responses does not reduce myocardial damage or PMNL accumulation following coronary artery occlusion with reperfusion. Prostaglandins 37:597-613.
35. 4 in coronary artery disease and after coronary artery bypass surgery. Coronary Artery Dis. 4:899-904.
36. Roberts, W. G., T. J. Simon, R. G. Berlin, R. C. Haggitt, E. S. Snyder, W. F. Stenson, S. B. Hanauer, J. E. Reagan, A. Cagliola, W. K. Tanaka, S. Simon, and M. L. Berger. 1997. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 112:725-732.